Next 10 |
home / stock / orn / orn articles
HOUSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company", "Orion"), a leading specialty construction comp...
U.S. stock futures were lower this morning, with the Dow futures falling around 250 points on Friday. Shares of RH (NYSE:RH) fell sharply in today&...
HOUSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company"), a leading specialty construction company, today...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday. The Dow traded down 1.55% to 3...
HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company"), a leading specialty construction comp...
HOUSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) ("Orion" or the "Company"), a leading specialty construction c...
HOUSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company"), a leading specialty construction compa...
HOUSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company"), a leading specialty construction company, toda...
HOUSTON, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE:ORN) (the "Company"), a leading specialty construction company, anno...
News, Short Squeeze, Breakout and More Instantly...
Orion Group Holdings Inc. Common Company Name:
ORN Stock Symbol:
NYSE Market:
Orion Group Holdings Inc. Common Website:
Orion Group Holdings, Inc. (NYSE: ORN) is one of today's top gainers. The company's shares have moved 13.47% on the day to $6.15. Orion Group Holdings, Inc. operates as a specialty construction company in the building, industrial, and infrastructure sectors in the continental United States, Al...
HOUSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today reported its financial results for the third quarter ended September 30, 2024. Highlights for the quarter ended September 30, 2024...
Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, presented at the 37th ECNP annual conference in September Company moving forward with PORTICO-2 Phase III trial preparations following positive feedback from End-of-Phase II meeting with the FDA Company continues ...